Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy

Authors :: Stefania Cuzzubbo
Marica Eoli
Maria Grazia Bruzzone
Eugenio Parati
Gaetano Finocchiaro
Carlo Antozzi
Simona Frigerio
Serena Pellegatta
Elena Anghileri
Lucia Cuppini
Renato Mantegazza
Valeria Cuccarini
Source :: Journal of Clinical Oncology. 32:2087-2087
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 2087 Background: DENDR1 is a phase I-II phase study aimed at evaluating dendritic cell (DC) immunotherapy in patients with first diagnosis of glioblastoma multiforme (GBM). Here we provide results ...

Subjects :: Cancer Research
business.industry
medicine.medical_treatment
Dendritic cell
Immunotherapy
Natural killer T cell
medicine.disease
nervous system diseases
Oncology
Cancer research
Medicine
In patient
Progression-free survival
business
Glioblastoma

Tools